Biocartis Group NV's latest marketcap:
As of 08/11/2025, Biocartis Group NV's market capitalization has reached $31.71 M. According to our data, Biocartis Group NV is the 33480th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 31.71 M |
| Revenue (ttm) | 55.53 M |
| Net Income (ttm) | 21.4 M |
| Shares Out | 93.92 M |
| EPS (ttm) | 0.23 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/29/2025 |
Biocartis Group NV's yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/11/2025 | €27.24 M | $31.71 M | 0% | 33480 |
| 12/31/2024 | €27.24 M | $28.19 M | 0% | 31882 |
| 12/29/2023 | €27.24 M | $30.06 M | -43.87% | 31153 |
| 12/30/2022 | €48.52 M | $51.93 M | -76.68% | 26594 |
| 12/31/2021 | €208.03 M | $236.44 M | -22.26% | 17856 |
| 12/31/2020 | €267.59 M | $326.83 M | -17.03% | 14063 |
| 12/31/2019 | €322.51 M | $361.62 M | -36.83% | 11703 |
| 12/31/2018 | €510.53 M | $585.37 M | -16.33% | 8337 |
| 12/29/2017 | €610.16 M | $731.83 M | 24.63% | 8581 |
| 12/30/2016 | €489.57 M | $514.83 M | -8.59% | 9386 |
Company Profile
About Biocartis Group NV
Biocartis Group NV is a molecular diagnostics company dedicated to enhancing clinical practice for patients, clinicians, payers, and the healthcare industry, with a primary focus on oncology.
Key Products & Solutions
The company's proprietary Idylla platform is a real-time polymerase chain reaction (PCR) system that delivers actionable molecular insights for treatment selection and monitoring. Key offerings include:
- Idylla Mutation Tests: BRAF, KRAS, MSI, EGFR, and NRAS-BRAF.
- Infectious Disease Panels: SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests.
- SeptiCyte RAPID: A rapid host-response test for sepsis.
Research & Development
Biocartis also provides research products such as:
- MSI, KRAS, BRAF, ctEGFR, and NRAS-BRAF-EGFR S492R mutation assays.
- GeneFusion, ctKRAS, ctBRAF, and ctNRAS-BRAF-EGFR S492R tests.
Strategic Collaborations
- Amgen: Evaluating Idylla RAS testing for decentralized diagnostics.
- Bristol-Myers Squibb: Registration of Idylla MSI test for immuno-oncology therapies.
- GeneproDx: Development of ThyroidPrint genomic test on the Idylla platform.
- APIS Assay Technologies: Collaboration on a breast cancer subtyping test.
Founded: 2007 | Headquarters: Mechelen, Belgium
Frequently Asked Questions
-
What is Biocartis Group NV's (EBR-BCART) current market cap?As of 08/11/2025, Biocartis Group NV (including the parent company, if applicable) has an estimated market capitalization of $31.71 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Biocartis Group NV (EBR-BCART) rank globally by market cap?Biocartis Group NV global market capitalization ranking is approximately 33480 as of 08/11/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.